US · ONC · BIOTECHNOLOGY
BeOne Medicines AG (ONC) intrinsic value and stock valuation
$390.94as of 2026-11-21 · Mkt cap 37.22B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
BeOne Medicines AG DCF and intrinsic value
InvestorsCraft values ONC with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from ONC’s statements →
BeOne Medicines AG Graham Number
Graham Number: $48.65d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2013–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Humana Inc. (HUM) $389.91
- Natera, Inc. (NTRA) $273.40
- Agilent Technologies, Inc. (A) $170.38
- IQVIA Holdings Inc. (IQV) $245.82
- Alcon Inc. (ALC) $74.31
- GE HealthCare Technologies Inc. (GEHC) $80.64
- ResMed Inc. (RMD) $235.63
- Mettler-Toledo International Inc. (MTD) $1,666.88
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B |
| Operating income | $447.1M | -$-568.2M | -$-1.21B | -$-1.79B | -$-1.44B |
| Net income | $286.9M | -$-644.79M | -$-881.71M | -$-2B | -$-1.46B |
| EPSd | $2.53M | -$-6.12M | -$-8.45M | -$-19.43M | -$-15.71M |
| Operating cash flow | $1.13B | -$-140.63M | -$-1.16B | -$-1.5B | -$-1.3B |
| Capital expenditure | -$-185.84M | -$-529.14M | -$-596.26M | -$-469.1M | -$-314.85M |
| Free cash flow | $941.7M | -$-669.77M | -$-1.75B | -$-1.97B | -$-1.61B |
| Total assets | $8.19B | $5.92B | $5.81B | $6.38B | $8.54B |
| Total debt | $2B | $1.08B | $930.2M | $596.7M | $694.6M |
| Net debt | -$-2.55B | -$-1.55B | -$-2.24B | -$-3.27B | -$-3.68B |
| Total equity | $4.36B | $3.33B | $3.54B | $4.38B | $6.13B |
| Cash and short-term investments | $4.55B | $2.63B | $3.17B | $4.53B | $6.62B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B |
| Cost of revenue | $668.5M | $594.1M | $379.9M | $286.5M | $164.9M |
| Gross profit | $4.67B | $3.22B | $2.08B | $1.13B | $1.01B |
| Research and development expenses | $2.15B | $1.95B | $1.78B | $1.64B | $1.46B |
| Selling, general and administrative expenses | $2.08B | $1.83B | $1.51B | $1.28B | $990.1M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $750K |
| Operating expenses | $4.23B | $3.78B | $3.29B | $2.92B | $2.45B |
| Cost and expenses | $4.9B | $4.38B | $3.67B | $3.21B | $2.62B |
| Interest income | $70.5M | $47.8M | $74M | $52.5M | $15.8M |
| Interest expense | $58.2M | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $141.7M | $171.8M | $87.7M | $66.3M | $46.5M |
| Ebitda | $616.8M | -$-361.24M | -$-738.16M | -$-1.89B | -$-1.39B |
| Operating income | $447.1M | -$-568.2M | -$-1.21B | -$-1.79B | -$-1.44B |
| Total other income/expenses, net | -$-30.28M | $35.2M | $381.9M | -$-171.37M | $150K |
| Income before tax | $416.9M | -$-533M | -$-825.84M | -$-1.96B | -$-1.44B |
| Income tax expense | $129.9M | $111.8M | $55.9M | $42.8M | $19.2M |
| Net income | $286.9M | -$-644.79M | -$-881.71M | -$-2B | -$-1.46B |
| Weighted average shares outstanding | $109.1M | $105.3M | $104.4M | $103.1M | $92.8M |
| Weighted average diluted shares outstanding | $113.5M | $105.3M | $104.4M | $103.1M | $92.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.55B | $2.63B | $3.17B | $4.53B | $6.62B |
| Net receivables | $886.9M | $709.1M | $395.9M | $199M | $500.2M |
| Inventory | $608.2M | $495M | $416.1M | $282.4M | $242.6M |
| Total current assets | $6.23B | $3.99B | $4.2B | $5.21B | $7.61B |
| Property, plant and equipment, net | $1.79B | $1.66B | $1.37B | $924M | $662.5M |
| Goodwill and intangible assets | $62.7M | $129.8M | $108.9M | $94.6M | $103.5M |
| Long-term investments | $82.5M | $128.9M | $89.6M | $91.8M | $100.8M |
| Total non-current assets | $1.95B | $1.93B | $1.6B | $1.17B | $921.6M |
| Total assets | $8.19B | $5.92B | $5.81B | $6.38B | $8.54B |
| Accounts payable | $479M | $405M | $315.1M | $294.8M | $262.4M |
| Short-term debt | $134.7M | $869.1M | $710.3M | $353M | $449.5M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $213.9M | $187.4M |
| Total current liabilities | $1.83B | $2.21B | $1.81B | $1.47B | $1.6B |
| Long-term debt | $1.87B | $210.8M | $219.9M | $243.7M | $245.2M |
| Deferred revenue, non-current | $0.00 | $30.3M | $34.2M | $80.2M | $266.6M |
| Total non-current liabilities | $2.01B | $373.8M | $457.8M | $527.4M | $803.4M |
| Capital lease obligations | $52.9M | $61.9M | $44.2M | $58.6M | $65M |
| Total liabilities | $3.83B | $2.59B | $2.27B | $2B | $2.4B |
| Common stock | $140K | $140K | $140K | $140K | $130K |
| Retained earnings | -$-8.32B | -$-8.61B | -$-7.96B | -$-7.08B | -$-5.08B |
| Accumulated other comprehensive income (loss) | -$-78.18M | -$-148.99M | -$-99.45M | -$-77.42M | $18M |
| Total equity | $4.36B | $3.33B | $3.54B | $4.38B | $6.13B |
| Total investments | $82.5M | $128.9M | $92.2M | $757M | $2.34B |
| Total debt | $2B | $1.08B | $930.2M | $596.7M | $694.6M |
| Net debt | -$-2.55B | -$-1.55B | -$-2.24B | -$-3.27B | -$-3.68B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $286.9M | -$-644.79M | -$-881.71M | -$-2B | -$-1.41B |
| Depreciation and amortization | $141.7M | $171.8M | $87.7M | $66.3M | $46.5M |
| Stock-based compensation | $510.9M | $441.6M | $367.6M | $303.2M | $240.7M |
| Change in working capital | $191.4M | -$-157.17M | -$-370.54M | $132.4M | -$-118.34M |
| Accounts receivable | -$-164.95M | -$-329.44M | -$-188.31M | $304.1M | -$-423.02M |
| Inventory | -$-93.17M | -$-91.5M | -$-140.95M | -$-56.69M | -$-153.33M |
| Accounts payable | $79.8M | $121.5M | $21.5M | -$-4.35M | $20M |
| Net cash provided by operating activities | $1.13B | -$-140.63M | -$-1.16B | -$-1.5B | -$-1.3B |
| Investments in property, plant and equipment | -$-185.84M | -$-492.66M | -$-561.9M | -$-469.1M | -$-314.85M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-1.4B | $51.9M |
| Net cash used for investing activities | -$-276.15M | -$-548.35M | $60M | $1.08B | $640.7M |
| Common stock issued | $196.8M | $0.00 | $0.00 | $0.00 | $3.44B |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $1.06B | $193.5M | $416.5M | -$-18.97M | $3.64B |
| Net change in cash | $1.97B | -$-547.24M | -$-689.05M | -$-507.85M | $2.99B |
| Cash at end of period | $4.61B | $2.64B | $3.19B | $3.88B | $4.38B |
| Operating cash flow | $1.13B | -$-140.63M | -$-1.16B | -$-1.5B | -$-1.3B |
| Capital expenditure | -$-185.84M | -$-529.14M | -$-596.26M | -$-469.1M | -$-314.85M |
| Free cash flow | $941.7M | -$-669.77M | -$-1.75B | -$-1.97B | -$-1.61B |
Line items
Line items
Line items
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
- CEO
- John V. Oyler
- Employees
- 12K
- Beta
- 0.49
Explore
Frequently asked questions
What is the intrinsic value of BeOne Medicines AG (ONC)?
BeOne Medicines AG (ONC) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ONC undervalued?
ONC trades at a price of $390.94 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.